Divergent Immunological and Neurotrophic Responses to CD20 Depletion in Relapsing and Progressive Multiple Sclerosis - PubMed
2 days ago
- #Neurotrophic Factors
- #Immunology
- #Multiple Sclerosis
- The study examines immunological and neurotrophic responses to CD20 depletion in relapsing (RMS) and progressive (PPMS) multiple sclerosis.
- Ocrelizumab, a CD20-targeting monoclonal antibody, is used for treating RMS and PPMS, but its effects on cytokines and neurotrophic factors are not fully understood.
- Baseline cytokine profiles differ between RMS and PPMS patients, with RMS showing higher levels of proinflammatory cytokines.
- Ocrelizumab treatment partially attenuates divergent cytokine profiles, with significant modulation of Th1-associated chemokines and increased BDNF in RMS patients.
- PPMS patients' cytokine signatures remain largely unaffected by ocrelizumab treatment.
- RMS patients with disease activity during the first 6 months of treatment show increased chemokines compared to those without activity or PPMS patients.
- Findings suggest divergent immunological mechanisms in RMS and PPMS, with stronger cytokine-driven pathology and immunomodulatory effects in RMS.